Press Release: BioAlliance Pharma : BioAlliance Pharma: Approval of Onxeo's admission to secondary listing and trading on NASDAQ OMX Copenhagen

PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE)--Regulatory News: In continuation of their joint company announcement of July 23, 2014, BioAlliance Pharma SA (Paris:BIO) (Euronext Paris - BIO), an innovative company specialized in the development of drugs in orphan oncology diseases newly renamed Onxeo, and Topotarget A/S (NASDAQ OMX Copenhagen - TOPO), today announce that NASDAQ OMX Copenhagen has approved Onxeo's admission to secondary trading and official listing on NASDAQ OMX Copenhagen to be